Consensus Cogent Biosciences, Inc.

Stocks

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 01/10/2026 +03			5-day change	1st Jan Change
31.59 ^USD	-1.34%		+0.57%	-11.06%

09-15	Cogent Biosciences, Inc. Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Advanced Systemic Mastocytosis	CI
09-15	Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application	MT

Evolution of the Average Target: Cogent Biosciences, Inc.

Evolution of the Target Price: Cogent Biosciences, Inc.

Changes in Analyst Recommendations: Cogent Biosciences, Inc.

247560e.5nVe4ghSUnA2162PGTzA3i0MlS4C-PFJGpI786pSoNY.oAE41WIUYRYDjuXdVhGI7ER532xsnZgrQtRssv0X4eKgHhq4YRkaJkG86A~fea574a27f4a6d3ad1d3c3f438b00381

Analysts' recommendations: Cogent Biosciences, Inc.

12-08	Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating	MT
11-11	Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13	MT
11-11	Sector Update: Health Care Stocks Advance Late Afternoon	MT
20/10/25	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib	CI
16/10/25	Stifel Nicolaus Initiates Coverage on Cogent Biosciences With Hold Rating, $16 Price Target	MT
03/09/25	Raymond James Initiates Cogent Biosciences at Strong Buy	MT
05/08/25	Wedbush Ups Price Target on Cogent Biosciences to $13 From $10, Maintains Neutral Rating	MT
07/07/25	Jefferies Adjusts Price Target on Cogent Biosciences to $28 From $23, Maintains Buy Rating	MT
06/05/25	Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating	MT
11/12/24	Needham Downgrades Cogent Biosciences to Hold From Buy	MT
03/09/24	Wedbush Adjusts Cogent Biosciences Price Target to $11 From $10, Maintains Neutral Rating	MT
26/02/24	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT
26/02/24	Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	MT
23/02/24	Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	MT
08/02/24	Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	MT
15/12/23	HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	MT
11/12/23	Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	MT
08/12/23	JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	MT
08/06/23	HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	MT
28/04/23	Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	MT
15/03/23	Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	MT
14/03/23	Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	MT
05/01/23	SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	MT
14/12/22	Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	MT
13/12/22	Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COGENT BIOSCIENCES, INC.					+74.32%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+21.92%
	LONZA GROUP AG					+19.64%
	IQVIA HOLDINGS INC.					+7.4%
	REVOLUTION MEDICINES, INC.					+25.43%
	BEONE MEDICINES AG					+18.27%
	CELLTRION, INC.					+50.7%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+73.24%
	Average					+30.66%
	Weighted average by Cap.					+22.92%